Clinical Drug Investigation (2019) 39:889–890
https://doi.org/10.1007/s40261-019-00832-2

CORRECTION

Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel $Na_V1.7$ Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

Michael E. Rothenberg[1] · Michael Tagen[1] · Jae H. Chang[1] · Janel Boyce-Rustay[1] · Michel Friesenhahn[1] · David H. Hackos[1] · Avis Hains[1] · Dan Sutherlin[1] · Michael Ward[1] · William Cho[1]

Published online: 23 July 2019

Correction to: Clinical Drug Investigation
https://doi.org/10.1007/s40261-019-00807-3

The original version of this article unfortunately contained a mistake. A few entries were incorrect in Table 2.

The corrected Table 2 is given in the following page.

The original article has been corrected.

The original article can be found online at https://doi.org/10.1007/s40261-019-00807-3.

✉ Michael E. Rothenberg
rothenberg.michael@gene.com

[1] Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Table 2 Treatment-emergent AEs in ≥ 5% of GDC-0276-treated subjects: SD-PIC, SD-CD, and MD-PIC cohorts (all causalities)

Preferred term	Placebo [*n* = 16]	2 mg [*n* = 12]	5 mg [*n* = 6]	15 mg [*n* = 6]	45 mg [*n* = 6]	90 mg [*n* = 6]	180 mg [*n* = 6]	270 mg [*n* = 6]	Total GDC-0276 [*n* = 48]
SD-PIC									
Any preferred term[a]	8 (50.0) [30]	6 (50.0) [10]	3 (50.0) [4]	1 (16.7) [5]	4 (66.7) [11]	3 (50.0) [4]	2 (33.3) [2]	3 (50.0) [17]	22 (45.8) [53]
Headache	0	0	0	1 (16.7) [1]	0	0	1 (16.7) [1]	1 (16.7) [2]	3 (6.3) [4]

	Placebo [*n* = 12]	45 mg [*n* = 6]	90 mg [*n* = 6]	180 mg [*n* = 6]	270 mg [*n* = 6]	360 mg [*n* = 6]	540 mg [*n* = 5]	Total GDC-0276 [*n* = 35]
SD-CD								
Any preferred term[a]	10 (83.3) [32]	3 (50.0) [7]	6 (100) [22]	4 (66.7) [13]	6 (100) [49]	6 (100) [23]	5 (100) [48]	30 (85.7) [162]
γ-Glutamyltransferase increased	0	1 (16.7) [1]	0	1 (16.7) [1]	0	0	0	2 (5.7) [2]
Diarrhea	2 (16.7) [4]	0	0	1 (16.7) [1]	2 (33.3) [2]	2 (33.3) [2]	4 (80.0) [4]	9 (25.7) [9]
Abdominal pain	0	0	0	2 (33.3) [2]	2 (33.3) [2]	3 (50.0) [3]	1 (20.0) [1]	8 (22.9) [8]
Nausea	1 (8.3) [1]	0	2 (33.3) [2]	1 (16.7) [1]	2 (33.3) [2]	1 (16.7) [1]	1 (20.0) [1]	7 (20.0) [7]
Hypoesthesia oral	0	0	2 (33.3) [2]	0	1 (16.7) [1]	1 (16.7) [1]	2 (40.0) [2]	6 (17.1) [6]
Paresthesia oral	0	0	2 (33.3) [2]	1 (16.7) [1]	1 (16.7) [1]	1 (16.7) [1]	1 (20.0) [1]	6 (17.1) [6]
Dizziness	2 (16.7) [2]	0	1 (16.7) [1]	0	2 (33.3) [2]	2 (33.3) [2]	3 (60.0) [7]	8 (22.9) [12]
Headache	2 (16.7) [2]	0	0	0	3 (50.0) [6]	2 (33.3) [2]	0	5 (14.3) [8]
Dysgeusia	1 (8.3) [1]	0	3 (50.0) [3]	0	1 (16.7) [1]	0	0	4 (11.4) [4]
Paresthesia	0	0	1 (16.7) [1]	0	1 (16.7) [1]	1 (16.7) [1]	0	3 (8.6) [3]
Head discomfort	0	0	0	0	1 (16.7) [1]	0	1 (20.0) [1]	2 (5.7) [2]
Feeling cold	0	0	0	0	1 (16.7) [2]	0	3 (60.0) [3]	4 (11.4) [5]
Feeling drunk	0	0	0	0	2 (33.3) [2]	0	0	2 (5.7) [2]
Throat irritation	0	0	1 (16.7) [1]	0	0	0	2 (40.0) [2]	3 (8.6) [3]
Pharyngeal hypoesthesia	0	0	0	0	0	1 (16.7) [1]	1 (20.0) [1]	2 (5.7) [2]
Vision blurred	0	0	0	0	3 (50.0) [3]	0	1 (20.0) [1]	4 (11.4) [4]
Hypotension	0	0	0	0	1 (16.7) [1]	0	2 (40.0) [3]	3 (8.6) [4]
Pallor	0	0	0	0	1 (16.7) [1]	0	2 (40.0) [2]	3 (8.6) [3]
Sinus tachycardia	1 (8.3) [2]	1 (16.7) [1]	0	0	1 (16.7) [1]	0	0	2 (5.7) [2]

	Placebo [*n* = 14]	15 mg (5 mg tid) [*n* = 8]	50 mg (25 mg bid) [*n* = 8]	90 mg (45 mg bid) [*n* = 8]	180 mg (90 mg bid) [*n* = 16]	360 mg (180 mg bid) [*n* = 8]	540 mg (270 mg bid) [*n* = 8]	Total GDC-0276 [*n* = 56]
MD-PIC								
Any preferred term[a]	13 (92.9) [59]	8 (100) [50]	7 (87.5) [25]	8 (100) [66]	15 (93.8) [105]	7 (87.5) [68]	8 (100) [63]	53 (94.6) [377]
ALT increased	3 (21.4) [6]	4 (50.0) [9]	1 (12.5) [3]	2 (25.0) [2]	7 (43.8) [11]	2 (25.0) [3]	5 (62.5) [10]	21 (37.5) [38]
AST increased	3 (21.4) [3]	2 (25.0) [4]	0	1 (12.5) [1]	4 (25.0) [7]	2 (25.0) [2]	4 (50.0) [5]	13 (23.2) [19]
Blood pressure systolic increased	1 (7.1) [2]	0	0	1 (12.5) [1]	1 (6.3) [1]	2 (25.0) [2]	0	4 (7.1) [4]
γ-Glutamyltransferase increased	2 (14.3) [2]	2 (25.0) [2]	0	0	1 (6.3) [5]	0	0	3 (5.4) [7]
Diarrhea	0	1 (12.5) [1]	0	1 (12.5) [2]	1 (6.3) [1]	1 (12.5) [1]	4 (50.0) [8]	8 (14.3) [13]
Abdominal pain	1 (7.1) [1]	1 (12.5) [1]	0	0	0	0	4 (50.0) [7]	5 (8.9) [8]
Constipation	0	0	1 (12.5) [1]	0	1 (6.3) [1]	0	1 (12.5) [1]	3 (5.4) [3]
Nausea	0	1 (12.5) [1]	0	1 (12.5) [2]	0	0	1 (12.5) [1]	3 (5.4) [4]
Headache	0	0	0	2 (25.0) [6]	2 (12.5) [2]	3 (37.5) [5]	0	7 (12.5) [13]
Dizziness	0	1 (12.5) [1]	0	1 (12.5) [2]	0	1 (12.5) [1]	0	3 (5.4) [4]
Tachycardia	5 (35.7) [5]	2 (25.0) [6]	0	1 (12.5) [3]	3 (18.8) [12]	3 (37.5) [18]	1 (12.5) [1]	10 (17.9) [40]
Medical device site pruritus	0	0	0	2 (25.0) [2]	1 (6.3) [1]	1 (12.5) [1]	0	4 (7.1) [4]
Fatigue	0	1 (12.5) [1]	0	0	1 (6.3) [1]	1 (12.5) [1]	0	3 (5.4) [3]

Data are expressed as no. of subjects (%) [no. of AEs]

Laboratory AEs may not correlate to actual data because not every laboratory abnormality was considered to be an AE

AEs adverse events, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *bid* twice daily, *CD* cyclodextrin, *MD* multiple dose, *PIC* powder-in-capsule, *SD* single dose, *tid* three times daily

[a] Data include all safety-evaluable subjects in each stage